Constellation Pharmaceuticals Inc. (NASDAQ:CNST) went down by -25.03% from its latest closing price compared to the recent 1-year high of $50.90. The company’s stock price has collected -26.43% of loss in the last five trading sessions. Press Release reported 18 hours ago that Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
Is It Worth Investing in Constellation Pharmaceuticals Inc. (NASDAQ :CNST) Right Now?
Opinions of the stock are interesting as 8 analysts out of 11 who provided ratings for Constellation Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $47.56, which is $21.0 above the current price. CNST currently public float of 47.22M and currently shorts hold a 12.40% ratio of that float. Today, the average trading volume of CNST was 590.79K shares.
CNST’s Market Performance
CNST stocks went down by -26.43% for the week, with a monthly drop of -23.58% and a quarterly performance of 14.85%, while its annual performance rate touched -26.59%. The volatility ratio for the week stands at 10.09% while the volatility levels for the past 30 days are set at 7.41% for Constellation Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -21.37% for CNST stocks with a simple moving average of -4.07% for the last 200 days.
Analysts’ Opinion of CNST
Many brokerage firms have already submitted their reports for CNST stocks, with BMO Capital Markets repeating the rating for CNST by listing it as a “Outperform.” The predicted price for CNST in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on January 25th of the current year 2021.
CNST Trading at -16.94% from the 50-Day Moving Average
After a stumble in the market that brought CNST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.52% of loss for the given period.
Volatility was left at 7.41%, however, over the last 30 days, the volatility rate increased by 10.09%, as shares sank -22.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.00% lower at present.
During the last 5 trading sessions, CNST fell by -26.43%, which changed the moving average for the period of 200-days by -44.70% in comparison to the 20-day moving average, which settled at $34.22. In addition, Constellation Pharmaceuticals Inc. saw -5.49% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CNST starting from Reeve Emma, who sale 6,260 shares at the price of $37.60 back on Feb 22. After this action, Reeve Emma now owns 0 shares of Constellation Pharmaceuticals Inc., valued at $235,373 using the latest closing price.
Reeve Emma, the Chief Financial Officer of Constellation Pharmaceuticals Inc., sale 4,010 shares at $37.71 during a trade that took place back on Feb 19, which means that Reeve Emma is holding 0 shares at $151,218 based on the most recent closing price.
Stock Fundamentals for CNST
The total capital return value is set at -35.66, while invested capital returns managed to touch -35.64. Equity return is now at value -28.90, with -25.00 for asset returns.
Based on Constellation Pharmaceuticals Inc. (CNST), the company’s capital structure generated 12.13 points at debt to equity in total, while total debt to capital is 10.82. Total debt to assets is 10.26, with long-term debt to equity ratio resting at 11.38. Finally, the long-term debt to capital ratio is 10.14.
The liquidity ratio also appears to be rather interesting for investors as it stands at 17.01.